NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Jennifer E Amengual
Columbia University New York - New York / United States
Medical and Health Sciences / Hematology
AD Scientific Index ID: 912934
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Jennifer E Amengual's MOST POPULAR ARTICLES
1-)
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLM Kalac, L Scotto, E Marchi, J Amengual, VE Seshan, G Bhagat, ...Blood, The Journal of the American Society of Hematology 118 (20), 5506-5516, 20111582011
2-)
Outcomes of patients with double-hit lymphoma who achieve first complete remissionDJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ...Journal of Clinical Oncology 35 (20), 2260, 20171292017
3-)
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJE Amengual, R Lichtenstein, J Lue, A Sawas, C Deng, E Lichtenstein, ...Blood, The Journal of the American Society of Hematology 131 (4), 397-407, 20181152018
4-)
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\'s lymphoma: an international, multicentre, single-arm, phase 1–2 trialOA O\'Connor, JK Lue, A Sawas, JE Amengual, C Deng, M Kalac, L Falchi, ...The Lancet Oncology 19 (2), 257-266, 20181282018
5-)
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 studyOA O’Connor, L Falchi, JK Lue, E Marchi, C Kinahan, A Sawas, C Deng, ...Blood, The Journal of the American Society of Hematology 134 (17), 1395-1405, 20191222019
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept